LipoScience Announces Appointment Of William Cromwell, M.D., As Chief Medical Officer
RALEIGH, N.C., Sept. 6, 2013 /PRNewswire/ — LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced the appointment of William Cromwell, M.D. as Chief Medical Officer.
“We are delighted to welcome Dr. William Cromwell back to LipoScience,” said Bob Greczyn, interim chief executive officer, LipoScience, Inc. “Dr. Cromwell’s achievements and expertise as an opinion leader in lipid and lipoprotein disorders make him an ideal addition to our team as we continue to grow as a leader in advancing the quality of patient care in cardiovascular, metabolic and other lipid-related diseases.”
Dr. Cromwell is an internationally recognized expert in the management of lipid and lipoprotein disorders. In addition to being board certified by the American Board of Clinical Lipidology, Dr. Cromwell is a fellow of the American Heart Association Council on Atherosclerosis, Thrombosis and Vascular Biology, Fellow of the National Lipid Association and Fellow of the American Academy of Family Physicians. He is also a member of the American Heart Association Council on Nutrition, Physical Activity, and Metabolism, as well as the Southeastern Lipid Association, and serves as Adjunct Associate Professor in the Hypertension and Vascular Disease Center at Wake Forest University School of Medicine. He joins LipoScience for a second time, having previously served as the company’s Chief Medical Officer from 1999 – 2005.
Dr. Cromwell joins LipoScience from the Lipoprotein and Metabolic Disorders Institute (LMDI) in Raleigh, North Carolina, which he founded in 1998 as a center of excellence for the comprehensive evaluation and management of lipid (cholesterol and triglyceride) disorders affecting patients of all ages, as well as the evaluation of early vascular disease. He received his doctoral degree in medicine from the Louisiana State University School of Medicine in New Orleans, Louisiana. He has also published over 20 peer-reviewed book chapters, review articles, and original research in lipid and lipoprotein disorders.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company’s first proprietary diagnostic test, the NMR LipoProfile(®) test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million NMR LipoProfile tests have been ordered. LipoScience’s automated clinical analyzer, Vantera(®), has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.
LipoScience is driving NMR diagnostics toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the Company’s plans, objectives, expectations (financial and otherwise) or intentions. These forward-looking statements include statements about the Company’s expectations for the future demand for its products and the factors that drive such demand. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Further information on potential factors and other risks that could affect the Company’s business and operating results is included in the Company’s Quarterly Report on Form 10-Q for the quarter ended July 31, 2013 and other filings the Company makes with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations page of the Company’s website at http://investor.liposcience.com/. The statements made herein are based on information available to LipoScience as of the date of this press release, and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
SOURCE LipoScience, Inc.